FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
-
-
-
-
-
-
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Compass Pathways receives FDA rolling review for psychedelic depression drug
-
-
-
-
-
-
-
Psychedelic stocks soar after Trump signs executive order to fast-track treatments
-
-
-
-
-
-
-
Compass Pathways (CMPS) PT Raised to $14 at Stifel
-
-
-
-
-
-
-
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026
-
-
-
-
-
-
-
Compass Pathways to release phase 3 psilocybin trial data feb 17
-
323,418 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

